Since PD-L1 status may be influenced by tumor heterogeneity, test variability, inter- and intra-observer variability, the clinical benefit is restricted to 15–20% of patients with non-oncogenic addicted NSCLC [3,4,5,6,7,8,9]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.